The present invention includes compositions and methods of making hydrophilic nanostructured antibiotics (i.e. nanoantibiotics), including nanoantibiotics that use environmentally degradable biomolecules as the backbone building blocks, wherein the backbone building blocks can include spherical backbones such as sucroses, cyclodextrins, glycogens, and phytoglycogen with different diameters, or rod-like backbone building blocks such as dextrins, amyloses, and celluloses with different lengths. These hydrophilic nanoantibiotics with well-defined sizes and shapes can selectively disrupt bacterial membranes (i.e., serve as membrane-active antimicrobials) while being benign to mammalian cells. Depending on the size and shape difference of the hydrophilic nanoantibiotics, they can also selectively kill one type of bacteria (e.g., gram-negative) over another type (e.g., gram-positive). The environmentally degradable nanoantibiotics will have built-in dismantling “switches” to dismantle and become antimicrobial inactive in responsive to environmental stimuli once released into natural habitat, hence greatly reducing the possibility of developing bacteria resistance.

The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.

The present invention relates to a certain microorganism for altering the composition of oral biofilms, in particular for use in the treatment and/or prevention of dental caries and/or periodontal disease. In particular, the present invention relates to a microorganism for use as a probiotic agent for altering the bacterial composition of oral biofilms derived from saliva, preferably for reducing the proportions of Gram-negative anaerobic genera and/or increasing the proportions of aerobic or facultatively anaerobic genera. Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising the microorganism as probiotic agents as well as a method of production thereof.

The disclosed invention provides an antibacterial pro-coagulant formula for assisting in combating the condition of bleeding gums caused by periodontal disease and gingivitis that enhances the natural healing process by assisting in the of cessation of bleeding by providing an “anti-bacterial oral healing environment” accompanied by enhanced blood flow to the affected bleeding area for more rapid blood clotting and increased blood flow to the affected area to assist the body's natural process of rebuilding healthy gum-tissue. Additionally, the disclosed invention with its antibacterial benefits, when used topically, provides for rapid surface skin blood clotting as well as increased blood circulation on the skin surface which greatly aids in the healing of external skin cuts, such as nicks from shaving or against inflammation of the skin from acne vulgaris. Continued use of the product orally and topically has proven to provide a beneficial stability to overall oral and skin health, especially useful in promoting healing in high-bacterial environments, such as is common in a person's mouth or on their face. Further described is a method of promoting hair follicle growth by application of the presented invention to a human scalp to promote blood flow to the scalp through below skin surface blood vessel dilation and below surface anti-bacterial cleansing of the scalp effecting an unrestricted and healthy skin tissue environment conducive to promoting hair follicle re-growth.

In one aspect, a method of treating smokeless tobacco addiction comprising administering to an individual in need thereof a pharmaceutical composition comprising nicotine, a therapeutically effective amount of cannabidiol, and a pharmaceutically acceptable vehicle therefor. In some aspects, the composition is administered transmucosally, such as in an oral dosage form or nasal spray. In other aspects, the composition is administered transdermally. In another aspect, a chewable gum contains nicotine in at least a base portion and cannabidiol in at least an outer portion thereof.

A chewing gum for mucosal delivery of cannabinoids, the chewing gum being formulated as an extruded chewing gum including water-soluble chewing gum ingredients mixed into water-insoluble gum base, wherein the chewing gum has one or more cannabinoids, and wherein the chewing gum generates saliva and delivers at least 10% by weight of the one or more cannabinoids to the oral mucosa during the first 5 minutes of chewing.

Described, among other things, are dosage forms for administration to a subject, the dosage forms having at least six ingredients are selected are from the group consisting of clove powder, rutin, hesperidin, baicalin, sulforaphane, moringa leaf extract, rosmarinic acid, guava leaf extract, Panax notoginseng, EGCG, propolis, coriander extract, cardamom extract, cinnamaldehyde, chlorogenic acid, caper fruit, vescalagin, nutmeg extract, and naringenin. The dosage forms can serve as inhibitors of quorum sensing by infectious agents. The described combinations of selected natural products have the ability to inhibit quorum sensing. Quorum sensing is a means by which bacteria and viruses communicate with each other and induce virulence in the body. This combination of natural products is preferably included in nutraceutical formulations in order to promote human immune health.

Water-soluble formulations including cannabinoids or a cannabis-derived compound for use in beverages and foods, methods of preparing the formulations, and methods of preparing beverages and foods including the formulations are disclosed herein. In other embodiments are provided water-soluble formulations that are physically and chemically stable, transparent or translucent in colour, calorie-free, and have minimal flavour.

The invention provides a probiotic formulation that includes an LDH-deficient mutans streptococcus strain and an attenuated S. oralis strain. S. uberis strains can be included in the probiotic formulation. Such a probiotic formulation is suitable for transiently colonizing the oral cavity with beneficial bacteria.

A composition comprising a combination of N-Phenylacetyl-L-prolylglycine ethyl ester and cannabidiol for oral administration to humans and other animals and a method for administering said composition are described. The composition provides synergistic nootropic benefits to the user, resulting in enhanced cognitive functions, such as increased focus, creativity, memory recall, and memory consolidation, among other cognitive functions. The composition generally does not cause side effects in the users and generally does not cause the user to develop tolerance to its nootropic effects. The composition optionally comprises a compound containing choline or a choline prodrug to supply choline to the brain of the user for the production of the neurotransmitter acetylcholine, and may also optionally comprise caffeine.